Equity Capital Markets

Award winning and top tier capital markets practice in Hong Kong

Our award winning and top tier capital markets practice in Hong Kong has advised on some of the most important IPOs of PRC and international companies in recent years:

We have advised the sponsors on the listings of:

Union Medical Healthcare Limited, YiChang HEC ChangJiang Pharmaceutical, The People's Insurance Company (Group) of China Limited (PICC), New China Life Insurance (NCI), China Pacific Insurance, Alibaba.com, Bank of Communications Company Limited, Fosun International, Agile Properties, Samson Holdings and the dual/triple listings and global offerings of Sinopec, China Unicom, Aluminum Corporation of China (Chalco) and China Telecom, raising between US$450 million and US$5.6 billion

We have advised the issuers on the listings of:

China Hengshi Foundation Company Limited, China Reinsurance (Group) Corporation (China Re), Golden Throat Company Limited, Chinalco Mining Corporation International, Metallurgical Corporation of China, Prada, Dongfeng Motor Group Company, China National Building Material Company, Semiconductor Manufacturing International Corporation (SMIC), MTR Corporation (Hong Kong’s first and to date only privatisation) and Prudential plc, raising between US$265 million and US$3.6 billion.

Our team of fluent Chinese (spoken Mandarin and written Chinese), US, Hong Kong and English qualified securities lawyers can provide a full service offering (including SEC-registered, Rule 144A/Regulation S, and Rule 144 offerings) and an unparalleled knowledge of the working practices and policies of the Hong Kong regulators.

Listing biotechnology companies on the Hong Kong Stock Exchange

The Hong Kong Stock Exchange (HKSE) has recently announced proposed rule changes to allow biotech companies to list in Hong Kong on a pre-revenue basis. It is expected that a new chapter to the Main Board Listing Rules (the Biotech Chapter) will be implemented as soon as late April, and biotech companies meeting the required criteria will be able to list under the Biotech chapter from the summer of 2018. This is an exciting time for Hong Kong’s equity capital markets, and at Slaughter and May we are uniquely equipped to help biotech companies and their sponsors prepare for and successfully list on the HKSE.

Our biotech equity capital markets team consists of:

  • senior lawyers who have extensive experience advising biotech companies on all aspects of their businesses, including those with graduate and postgraduate degrees in biochemistry, and career experience of biochemical research projects;
  • senior lawyers who have extensive knowledge of listings in Hong Kong under the new rules and procedures and who have strong relationships with the key regulators; and
  • an experienced team who have been closely monitoring the new rules and their implications so that timely and practical advice can be given to the biotech applicant and its sponsor in relation to the applicant’s listing application pursuant to the new Biotech Chapter.

Please see more about our experience in English and in Chinese and read our March 2018 Client Briefing, Listings of Innovative Companies in Hong Kong, which sets out an overview and analysis of the new regime.


Partner Contacts


The firm is commended for its ‘thorough analysis’ and 'strong relationship with regulators' The Legal 500 Asia Pacific, 2016